Description: Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Home Page: www.sigilon.com
SGTX Technical Analysis
100 Binney Street
Cambridge,
MA
02142
United States
Phone:
617 336 7540
Officers
| Name | Title |
|---|---|
| Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA | Pres, CEO & Director |
| Dr. Daniel G. Anderson Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Philip Ashton-Rickardt Ph.D. | Chief Scientific Officer |
| Dr. May Orfali M.B.A., M.D. | Exec. VP & Chief Medical Officer |
| Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Member of Scientific Advisory Board |
| Dr. Omid Veiseh Ph.D. | Co-Founder |
| Dr. José Oberholzer M.D. | Co-Founder |
| Dr. Arturo Vegas Ph.D. | Co-Founder |
| Mr. Josias Fantato De Pontes M.B.A. | Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer |
| Mr. Robert Windsor Jr., J.D. | VP & Head of Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 2.7655 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2521 |
| Price-to-Sales TTM: | 0.8715 |
| IPO Date: | 2020-12-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 66 |